Taking stock of the drug industry, from the lab to the medicine chestJuly 22, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Molly Ferguson for STAT STAT+ | Drugmakers are racing to help patients stay awake — and could also make billions Takeda, Alkermes, and Centessa lead a race to develop orexin drugs that could transform narcolepsy treatment and tackle a range of other sleep issues. By Elaine Chen STAT+ | Sarepta Therapeutics' Duchenne therapy faces 'arduous' path back to market, senior FDA official says FDA insider suggests Sarepta's gene therapy for Duchenne muscular dystrophy may never return to market. By Adam Feuerstein and Jason Mast STAT+ | Replimune skin cancer therapy rejected by FDA, a sign of regulators' hardened stance The FDA's decision is the latest indication that the agency is taking a hardened stance on drug approvals under regulatory Vinay Prasad. By Adam Feuerstein Anna Yeo/STAT STAT+ | Sanofi to buy vaccine biotech Vicebio for $1.15B upfront Vicebio's lead candidate is designed to protect against both RSV and human metapneumovirus, known as hMPV. By Andrew Joseph Study of GLP-1 guidelines for teens points to potential for influence from drugmakers More than one-third of people who developed guidelines for treating children with obesity had financial ties to obesity drugmakers, a paper finds. By Isabella Cueto More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments